SUNRAY-02
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- NCT06890598 ↗
- Recruiting
- Eli Lilly and Company
- Focused
We haven't built an HCP commentary report on SUNRAY-02 (olomorasib plus pembrolizumab; olomorasib plus durvalumab in stage II-III KRAS G12C-mutant non-small cell lung cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on SUNRAY-02 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 6 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination With Standard of Care Immunotherapy in Participants With Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Olomorasib; Pembrolizumab; Durvalumab; Placebo
- Arms
- Part A: Olomorasib + Pembrolizumab · Experimental
- Part A: Placebo + Pembrolizumab · Placebo comparator
- Part B: Olomorasib + Durvalumab · Experimental
- Part B: Placebo + Durvalumab · Placebo comparator
- Enrollment
- 700 (estimated)
- Primary outcomes
- Part A: Disease-Free Survival (DFS) by Investigator Assessment
- Part B: Progression-Free Survival (PFS) by BICR
- Sponsor
- Eli Lilly and Company with AstraZeneca
- Start
- Mar 27, 2025
- Primary completion
- May 2029 (estimated)
- Results posted
- No
- Registry record
- NCT06890598 · updated Nov 4, 2026
Publications
linked from the registry- Chaft J, Lee JM, Senan S, Neal JW, Nadal E, Negrao MV, Popat S, Garassino MC, Gray JE, Lee SH, Mazieres J, Thomas M, Benes M, Liu H, Liu J, Ma QL, Segall G, Puri T, Wu YL. SUNRAY-02: a study of olomorasib combined with immunotherapy in stage II-III KRAS G12C-mutant non-small cell lung cancer after definitive therapy. Future Oncol. 2026 Oct 1:1-10. doi: 10.1080/14796694.2026.2736401. Online ahead of print. PubMed 42823821